SIRPA and neoplasm: It is important to note that targeting tumor cells with CD47-specific blocking antibodies or soluble signal regulatory protein-α (SIRPα) variants inhibits CD47- SIRPα interaction and facilitates tumor cell removal by macrophages, leading to reduction tumor growth and metastasis [40–44].